Back to Search

Velpatasvir,Sofosbuvir,Voxilaprevir – Uses, Dosage, and Brands in UAE

Brand Name: VOSEVI
Strength: 400 mg,100 mg,100 mg | Form: Tablets
Price in UAE: AED 101847.00
Available in UAE pharmacies

About Velpatasvir,Sofosbuvir,Voxilaprevir

Class: | Antiviral agent (HCV NS5A inhibitor, HCV NS5B polymerase inhibitor, HCV protease inhibitor) Use: | Treatment of chronic hepatitis C virus (HCV) infection in adults and pediatric patients 12 years and older, with or without cirrhosis, and in those who have not been previously treated or have been treated with other direct-acting antiviral agents. Adult dose: | One tablet (400 mg Velpatasvir, 100 mg Sofosbuvir, 100 mg Voxilaprevir) taken orally once daily with or without food for 12 w

Drug Class

Antiviral agent (HCV NS5A inhibitor, HCV NS5B polymerase inhibitor, HCV protease inhibitor)

Uses & Indications

Treatment of chronic hepatitis C virus (HCV) infection in adults and pediatric patients 12 years and older, with or without cirrhosis, and in those who have not been previously treated or have been treated with other direct-acting antiviral agents.

Storage Requirements

Store at room temperature (20°C to 25°C or 68°F to 77°F) in a tightly closed container, protected from moisture and light.

Manufacturer & Packaging

Manufacturer: Gilead Sciences International Ltd., UNITED KINGDOM

Package Size

28s

Price & Supplier

Price in UAE: AED 101847.00

Dosage Information

Adult Dose

One tablet (400 mg Velpatasvir, 100 mg Sofosbuvir, 100 mg Voxilaprevir) taken orally once daily with or without food for 12 weeks.

Pediatric Dose

Not established for patients under 12 years of age; safety and efficacy have not been determined in this population.

Side Effects

Fatigue, headache, nausea, diarrhea, insomnia, and potential liver enzyme elevations.

Contraindications & Precautions

Co-administration with strong inducers of CYP3A (e.g., rifampin, St. John's Wort) and in patients with a history of hypersensitivity to any component of the formulation.

Important Warnings

Risk of reactivation of hepatitis B virus (HBV) in patients co-infected with HBV and HCV; monitor HBV in these patients. Not recommended for use in patients with severe hepatic impairment (Child-Pugh Class C).

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication. The information presented here is specific to medicines available in UAE pharmacies and is regularly updated to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.

View All Antiviral agent (HCV NS5A inhibitor, HCV NS5B polymerase inhibitor, HCV protease inhibitor) Medicines Browse All Categories